NICE recommends Lenvima in new setting

8 November 2018

The National Institute for Health and Care Excellence (NICE) on Thursday recommended routine National Health Service (NHS) funding for first-line treatment with Lenvima (lenvatinib) in adults with untreated, advanced, unresectable hepatocellular carcinoma (HCC).

The NICE’s final appraisal document recommends using the oral receptor tyrosine kinase inhibitor in these HCC patients in England and Wales who have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Lenvima, which is being developed by Japanese drugmaker Eisai (TYO: 4523) in partnership with US pharma giant Merck & Co (NYSE: MRK), is the first new, approved first-line treatment for advanced or unresectable HCC in a decade to show an overall survival treatment effect that was non-inferior to the current standard of care, which is Bayer’s (BAYN: DE) Nexavar (sorafenib).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK